INmune Bio Overview
INmune Bio (INMB) has a P/E ratio of -3.22, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-3.22
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, INMB shows a P/E ratio of -3.22. That is below the Healthcare sector average of 24.78. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 24.78. INmune Bio is at -3.22, which is lower that average. That is roughly 113.0% below the sector mean. Use the comparison chart on this page to see how INMB stacks up against individual peers as well.
Investors watch INMB's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. INmune Bio's latest reading is -3.22. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has INmune Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -3.22) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 24.78, while INMB is at -3.22. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
